Skip to main content
Top
Published in: Arthritis Research & Therapy 4/2012

Open Access 01-08-2012 | Research article

Autoantibody profiling to follow evolution of lupus syndromes

Authors: Nancy J Olsen, Quan-Zhen Li, Jiexia Quan, Ling Wang, Azza Mutwally, David R Karp

Published in: Arthritis Research & Therapy | Issue 4/2012

Login to get access

Abstract

Introduction

Identification of patients who are in early stages of lupus is currently done through clinical evaluation and is not greatly facilitated by available diagnostic tests. Profiling for patient characteristics and antibody specificities that predict disease would enhance the ability of physicians to identify and treat early cases prior to onset of organ damaging illness.

Methods

A group of 22 patients with 4 or fewer diagnostic criteria for lupus were studied for changes in clinical and autoantibody profiles after a mean follow up period of 2.4 years. An array with more than 80 autoantigens was used to profile immunoglobulin G (IgG) and immunoglobulin M (IgM) autoantibodies. Correlations with clinical disease progression were examined.

Results

3 of the 22 patients (14%) added sufficient criteria during follow up to satisfy a diagnosis of systemic lupus erythematosus (SLE) or to acquire a diagnosis of SLE renal disease. Patients who progressed were all females and were younger than those who did not progress (P=0.00054). IgG but not IgM autoreactivity showed greater increases in the progressor group than in the non-progressor group (P=0.047). IgG specificities that were higher at baseline in progressors included proliferating cell nuclear antigen (PCNA), beta 2 microglobulin, C1q and hemocyanin (P<0.019). Progressors had significant increases in La/SSB and liver cytosol type 1 (LC1) IgG autoantibodies over the period of evaluation (P≤0.0072). A quantitative risk profile generated from baseline demographic and autoantibody variables yielded highly different scores for the progressor and non-progressor groups (P=1.38 × 10-7)

Conclusions

In addition to demographic features, autoantibody profiles using an expanded array of specificities were correlated with the risk of progressive disease in patients with lupus. These findings suggest the feasibility of developing a simple diagnostic that could be applied by nonspecialists to screen for lupus and permit effective triage for specialty care.
Appendix
Available only for authorised users
Literature
1.
go back to reference Kurien BT, Scofield RH: Autoantibody determination in the diagnosis of systemic lupus erythematosus. Scand J Immunol. 2006, 64: 227-235.CrossRefPubMed Kurien BT, Scofield RH: Autoantibody determination in the diagnosis of systemic lupus erythematosus. Scand J Immunol. 2006, 64: 227-235.CrossRefPubMed
3.
go back to reference Meroni P, Schur P: ANA screening: an old test with new recommendations. Ann Rheum Dis. 2010, 69: 1420-1422.CrossRefPubMed Meroni P, Schur P: ANA screening: an old test with new recommendations. Ann Rheum Dis. 2010, 69: 1420-1422.CrossRefPubMed
4.
go back to reference Doria A, Zen M, Canova M, Bettio S, Bassi N, Nalotto L, Rampudda M, Ghirardello A, Iaccarino L: SLE diagnosis and treatment: when early is early. Autoimmun Rev. 2010, 10: 55-60.CrossRefPubMed Doria A, Zen M, Canova M, Bettio S, Bassi N, Nalotto L, Rampudda M, Ghirardello A, Iaccarino L: SLE diagnosis and treatment: when early is early. Autoimmun Rev. 2010, 10: 55-60.CrossRefPubMed
5.
go back to reference Sherer Y, Gorstein A, Fritzler MJ, Shoenfeld Y: Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Semin Arthritis Rheum. 2004, 34: 501-537.CrossRefPubMed Sherer Y, Gorstein A, Fritzler MJ, Shoenfeld Y: Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Semin Arthritis Rheum. 2004, 34: 501-537.CrossRefPubMed
6.
go back to reference Arbuckle M, McClain M, Rubertone M, Scofield R, Dennis G, James J, Harley J: Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003, 349: 1526-1533.CrossRefPubMed Arbuckle M, McClain M, Rubertone M, Scofield R, Dennis G, James J, Harley J: Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003, 349: 1526-1533.CrossRefPubMed
7.
go back to reference Laustrup H, Voss A, Green A, Junker P: Occurrence of systemic lupus erythematosus in a Danish community: an 8-year prospective study. Scand J Rheumatol. 2009, 38: 128-132.CrossRefPubMed Laustrup H, Voss A, Green A, Junker P: Occurrence of systemic lupus erythematosus in a Danish community: an 8-year prospective study. Scand J Rheumatol. 2009, 38: 128-132.CrossRefPubMed
8.
go back to reference Fabio G, Carrabba M, Hu C, Floriani M, Besana C: Dramatic development of severe SLE in a patient with an incomplete disease. Rheumatol Int. 2005, 25: 543-547.CrossRefPubMed Fabio G, Carrabba M, Hu C, Floriani M, Besana C: Dramatic development of severe SLE in a patient with an incomplete disease. Rheumatol Int. 2005, 25: 543-547.CrossRefPubMed
9.
go back to reference Li Q, Zhou J, Wandstrat A, Carr-Johnson F, Branch V, Karp D, Mohan C, Wakeland E, Olsen N: Protein array autoantibody profiles for insights into systemic lupus erythematosus and incomplete lupus syndromes. Clin Exp Immunol. 2007, 147: 60-70.PubMedCentralPubMed Li Q, Zhou J, Wandstrat A, Carr-Johnson F, Branch V, Karp D, Mohan C, Wakeland E, Olsen N: Protein array autoantibody profiles for insights into systemic lupus erythematosus and incomplete lupus syndromes. Clin Exp Immunol. 2007, 147: 60-70.PubMedCentralPubMed
10.
go back to reference Wandstrat A, Carr-Johnson F, Branch V, Gray H, Fairhurst A, Reimold A, Karp D, Wakeland E, Olsen N: Autoantibody profiling to identify individuals at risk for systemic lupus erythematosus. J Autoimmun. 2006, 27: 153-160.CrossRefPubMed Wandstrat A, Carr-Johnson F, Branch V, Gray H, Fairhurst A, Reimold A, Karp D, Wakeland E, Olsen N: Autoantibody profiling to identify individuals at risk for systemic lupus erythematosus. J Autoimmun. 2006, 27: 153-160.CrossRefPubMed
11.
go back to reference Li QZ, Karp DR, Quan J, Branch VK, Zhou J, Lian Y, Chong BF, Wakeland EK, Olsen NJ: Risk factors for ANA positivity in healthy persons. Arthritis Res Ther. 2011, 13: R38-PubMedCentralCrossRefPubMed Li QZ, Karp DR, Quan J, Branch VK, Zhou J, Lian Y, Chong BF, Wakeland EK, Olsen NJ: Risk factors for ANA positivity in healthy persons. Arthritis Res Ther. 2011, 13: R38-PubMedCentralCrossRefPubMed
13.
go back to reference Tan E, Cohen A, Fries J, Masi A, McShane D, Rothfield N, Schaller J, Talal N, Winchester R: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982, 25: 1271-1277.CrossRefPubMed Tan E, Cohen A, Fries J, Masi A, McShane D, Rothfield N, Schaller J, Talal N, Winchester R: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982, 25: 1271-1277.CrossRefPubMed
14.
go back to reference Hochberg MC: Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997, 40: 1725-CrossRefPubMed Hochberg MC: Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997, 40: 1725-CrossRefPubMed
15.
go back to reference Vilá LM, Mayor AM, Valentín AH, García-Soberal M, Vilá S: Clinical outcome and predictors of disease evolution in patients with incomplete lupus erythematosus. Lupus. 2000, 9: 110-115.CrossRefPubMed Vilá LM, Mayor AM, Valentín AH, García-Soberal M, Vilá S: Clinical outcome and predictors of disease evolution in patients with incomplete lupus erythematosus. Lupus. 2000, 9: 110-115.CrossRefPubMed
16.
go back to reference Maas K, Chan S, Parker J, Slater A, Moore J, Olsen N, Aune TM: Cutting edge: molecular portrait of human autoimmune disease. J Immunol. 2002, 169: 5-9.CrossRefPubMed Maas K, Chan S, Parker J, Slater A, Moore J, Olsen N, Aune TM: Cutting edge: molecular portrait of human autoimmune disease. J Immunol. 2002, 169: 5-9.CrossRefPubMed
18.
go back to reference Klareskog L, Gregersen PK, Huizinga TW: Prevention of autoimmune rheumatic disease: state of the art and future perspectives. Ann Rheum Dis. 2010, 69: 2062-2066.CrossRefPubMed Klareskog L, Gregersen PK, Huizinga TW: Prevention of autoimmune rheumatic disease: state of the art and future perspectives. Ann Rheum Dis. 2010, 69: 2062-2066.CrossRefPubMed
19.
go back to reference Monneaux F, Muller S: Epitope spreading in systemic lupus erythematosus: identification of triggering peptide sequences. Arthritis Rheum. 2002, 46: 1430-1438.CrossRefPubMed Monneaux F, Muller S: Epitope spreading in systemic lupus erythematosus: identification of triggering peptide sequences. Arthritis Rheum. 2002, 46: 1430-1438.CrossRefPubMed
20.
go back to reference Heinlen LD, McClain MT, Ritterhouse LL, Bruner BF, Edgerton CC, Keith MP, James JA, Harley JB: 60 kD Ro and nRNP A frequently initiate human lupus autoimmunity. PLoS One. 2010, 5: e9599-PubMedCentralCrossRefPubMed Heinlen LD, McClain MT, Ritterhouse LL, Bruner BF, Edgerton CC, Keith MP, James JA, Harley JB: 60 kD Ro and nRNP A frequently initiate human lupus autoimmunity. PLoS One. 2010, 5: e9599-PubMedCentralCrossRefPubMed
21.
go back to reference Routsias JG, Kyriakidis N, Latreille M, Tzioufas AG: RNA recognition motif (RRM) of La/SSB: the bridge for interparticle spreading of autoimmune response to U1-RNP. Mol Med. 2010, 16: 19-26.PubMedCentralCrossRefPubMed Routsias JG, Kyriakidis N, Latreille M, Tzioufas AG: RNA recognition motif (RRM) of La/SSB: the bridge for interparticle spreading of autoimmune response to U1-RNP. Mol Med. 2010, 16: 19-26.PubMedCentralCrossRefPubMed
22.
go back to reference Defendenti C, Atzeni F, Spina MF, Grosso S, Cereda A, Guercilena G, Bollani S, Saibeni S, Puttini PS: Clinical and laboratory aspects of Ro/SSA-52 autoantibodies. Autoimmun Rev. 2011, 10: 150-154.CrossRefPubMed Defendenti C, Atzeni F, Spina MF, Grosso S, Cereda A, Guercilena G, Bollani S, Saibeni S, Puttini PS: Clinical and laboratory aspects of Ro/SSA-52 autoantibodies. Autoimmun Rev. 2011, 10: 150-154.CrossRefPubMed
23.
go back to reference Sánchez-Guerrero J, Lew RA, Fossel AH, Schur PH: Utility of anti-Sm, anti-RNP, anti-Ro/SS-A, and anti-La/SS-B (extractable nuclear antigens) detected by enzyme-linked immunosorbent assay for the diagnosis of systemic lupus erythematosus. Arthritis Rheum. 1996, 39: 1055-1061.CrossRefPubMed Sánchez-Guerrero J, Lew RA, Fossel AH, Schur PH: Utility of anti-Sm, anti-RNP, anti-Ro/SS-A, and anti-La/SS-B (extractable nuclear antigens) detected by enzyme-linked immunosorbent assay for the diagnosis of systemic lupus erythematosus. Arthritis Rheum. 1996, 39: 1055-1061.CrossRefPubMed
24.
go back to reference James JA, Kim-Howard XR, Bruner BF, Jonsson MK, McClain MT, Arbuckle MR, Walker C, Dennis GJ, Merrill JT, Harley JB: Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus. Lupus. 2007, 16: 401-409.CrossRefPubMed James JA, Kim-Howard XR, Bruner BF, Jonsson MK, McClain MT, Arbuckle MR, Walker C, Dennis GJ, Merrill JT, Harley JB: Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus. Lupus. 2007, 16: 401-409.CrossRefPubMed
25.
go back to reference Heinlen LD, McClain MT, Merrill J, Akbarali YW, Edgerton CC, Harley JB, James JA: Clinical criteria for systemic lupus erythematosus precede diagnosis, and associated autoantibodies are present before clinical symptoms. Arthritis Rheum. 2007, 56: 2344-2351.CrossRefPubMed Heinlen LD, McClain MT, Merrill J, Akbarali YW, Edgerton CC, Harley JB, James JA: Clinical criteria for systemic lupus erythematosus precede diagnosis, and associated autoantibodies are present before clinical symptoms. Arthritis Rheum. 2007, 56: 2344-2351.CrossRefPubMed
Metadata
Title
Autoantibody profiling to follow evolution of lupus syndromes
Authors
Nancy J Olsen
Quan-Zhen Li
Jiexia Quan
Ling Wang
Azza Mutwally
David R Karp
Publication date
01-08-2012
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 4/2012
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar3927

Other articles of this Issue 4/2012

Arthritis Research & Therapy 4/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.